Fig. 6

EP300-ZNF384 positive B-cell acute lymphoblastic leukemia (B-ALL) cells are more sensitive to doxorubicin in vitro and in vivo. (A) Empty vector-, EP300-ZNF384-, and ZNF384-expressing NALM-6 cells were treated with increasing doses of doxorubicin for 48 h in the presence or absence of IL-3. Cell viability was determined by CCK-8 assay. Data are represented as mean ± SD. ***P < 0.001. (B) Empty vector-, EP300-ZNF384-, and ZNF384-expressing NALM-6 cells were treated with indicated doses of doxorubicin for 48 h. Cell apoptosis was detected by dual Annexin V-FITC/PI staining. Representative flow cytometry dot plots are presented (C) Column plots represents the proportion of Annexin V-positive cells. Data were represented as mean ± SD (n = 3). Unpaired t-test. *P < 0.05, ***P < 0.001. (D) Schematic describing generation of CDX mouse model by engrafting NOD⁃Prkdc^scidIl2rg^null (NYG) mice with NALM-6 cells harboring the empty vector, EP300-ZNF384, or ZNF384, followed directly by in vivo treatment with doxorubicin (8 mg/kg, intraperitoneally). (E) Percentage of human CD19⁺ subpopulations in the bone marrow of NYG mice engrafted with empty vector or EP300-ZNF384 or ZNF384 expressing NALM-6 cells, followed by in vivo doxorubicin treatment. (F) Leukemia involvement in the liver was determined by H&E staining. Scale bar indicates 50 μm